| |
|
|
|
Xtalks, Online
2024-05-07
Traditionally, the journey from biologics discovery to their development and initial human trials has followed a familiar route, sticking to established norms. It is now more vital than ever for biologics developers to obtain access to the most effective tools, technologies and machine learning strategies to mitigate hurdles during the scaling-up process.
In this webinar, the expert speakers will discuss the combined use of an open-source platform and hybrid–mechanistic process model that was developed using data sets from both stable bulk cultures (SBCs) and derivative clones using cell line technologies. This helps enable well-controlled SBCs, high titers, process robustness, scalability and speed-to-clinic.
The attendees will also learn about using SBC-based platforms, enabling companies to reduce the cost/time cycle of early development. They will also understand the importance of better alignment between biotechs and service providers (such as CROs and CDMOs) to effectively bridge the translation from preclinical to clinical development.
Register for this webinar today to gain insights into the most effective tools, technologies and strategies for biologics discovery and development.
Keywords: Clinical Development, CDMO/CMO, Pre-Clinical, Biologics Manufacturing, Cell and Gene Therapies, Cell Line Development, CDMO, Laboratory Technology, CMO, Drug Development, Biosimilars, CRO, Biotech, Clinical Research, Biologics, Drug Discovery, Preclinical, Biosimilar
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Brian R. Berquist, PhD, Chief Development Officer, Wheeler Bio, Inc.
Oren Beske, PhD, Amalgamator of Business and Biology, ATUM
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-05-07
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|